Phase II study of bortezomib for castrate metastatic prostate cancer (PC)

Autor:	K. W. Beekman, Tracy Curley, David R. Shaffer, Anthony Delacruz, Howard I. Scher, C. Eicher, Elaina Chu, Wm. Kevin Kelly, Susan F. Slovin, Michael J. Morris
Rok vydání:	2005
Předmět:	Cancer Research medicine.medical_specialty business.industry Bortezomib Phases of clinical research medicine.disease Prostate cancer Endocrinology Oncology Internal medicine Proteasome inhibitor medicine Cancer research In patient business medicine.drug
Zdroj:	Journal of Clinical Oncology. 23:4633-4633
ISSN:	1527-7755 0732-183X
Popis:	4633 Background: Bortezomib (VELCADE, Millennium Pharmaceuticals, Cambridge, MA) is a proteasome inhibitor that induced PSA declines in patients (pts) with castrate metastatic PC in phase I studies...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::42c8511a3ea3cad7b2ec11ca009d79f2 https://doi.org/10.1200/jco.2005.23.16_suppl.4633 Zobrazit plný text záznamu